Company intelligence / Profile preview

DyfucaMed

Ownership: Private
Development stage: Other

Overview

DyfucaMed's flagship product, the DyfucaMed Ratio Applicator, uses stem cell technology and controlled application of concentrated platelet gel to enable autogenous hematopoetic tissue grafts. The technology offers benefits including accelerated tissue regeneration, hemostasis creation, pain reduction, infection prevention, and reduced risk of adhesions.

Therapeutic areas: EndocrinologyCardiovascularNeurologyOther
Modalities: Stem cell therapyDevice
Industry: Surgical Medical Devices

Beyond the preview

Go deeper on DyfucaMed.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DyfucaMed.

Explore the full profile